It depends on what Monepantel is sold for; if at the Relyvrio (not around anymore) price of US158k & 38K patients = US6bn, then the target price will be (many times above PAA market cap).
I sincerely hope it won't be sold for that much and will be heavily subsidised and easily accessible. Who knows, Australia may benefit from medical tourism, one day.
Company Analysis - Morgans, page-5
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.46M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 18.5¢ | $177.2K | 929.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 499621 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 70000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |